Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes

• Status: Completed
• Trial end date: 2020-02-11
• Target enrollment: 0
• Participant gender: Male

Summary

In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in patients with T1D.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Steno Diabetes Center; Steno Diabetes Center Copenhagen
• Treatments: Gastric Inhibitory Polypeptide; Hormones; Incretins

Criteria

Inclusion Criteria:

• Caucasian men

• Body mass index between 20-27 kg/m^2

• T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c<69 mmol/l (<8,5%)

• T1D duration between 2-20 years

• Stimulated C-peptide ≤ 100 pmol/mL)

• Treatment with a stable basal bolus or insulin pump regimen ≥ 3 months

• Informed consent

Exclusion Criteria:

• Anemia (hemoglobin below normal range)

• Liver disease (ALAT and/or ASAT >2 times normal values) or history of hepatobiliary disorder

• Nephropathy (serum creatinine above normal range and/or albuminuria)

• Allergy or intolerance to ingredients included in the standardized meals

• Prior myocardial infarction or other cardiac events

• Any physical or psychological condition that the investigator fells would interfere with trial participation

• Treatment with any glucose-lowering drugs beside insulin